Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. on January 11, 2021. The filing serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. It acts solely as a conduit for the attached press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not disclose specific material changes versus prior periods. The content is limited to the notification of the press release issuance.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the Form 6-K text itself. These details are contained within the attached press release (Exhibit 99.1), which is not included in the input text.
Key Facts for Investor Verification
- Verify the full content of the press release dated January 11, 2021, referenced as Exhibit 99.1, as the Form 6-K contains no substantive operational or financial details.
- Confirm the company's status as a foreign private issuer filing under Form 20-F.
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on January 11, 2021.